#GNPX hashtag - Bluesky

2 months ago

#GNPX reaches new intraday high on volume, strong numbers reported. Algo-driven moves drive market momentum.

0 1 0 0

2 months ago

#GNPX spiking higher on volume after strong numbers and new intraday high at $3 Magnet.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#AAPL: 66
#META: 56
#TSLA: 53
#MSFT: 36
#SNDK: 28
#GOLD: 17
#GLD: 16
#NXXT: 15
#GNPX: 14
#AMZN: 11
#LUV: 11
#LITM: 10
#SPY: 10
#FED: 9
#EOSE: 9
#NUKK: 9
#GOOGL: 9
#PSQH: 8

0 0 0 0

2 months ago

#GNPX being targeted for invalidation, but low volume suggests failure; FDA meeting awaiting in Q1 2026

0 0 0 0

2 months ago

#GNPX breaking out, holding up nicely above $3 area and seeing significant volume increase

0 0 0 0

2 months ago

#GNPX breaking out, reaching new highs and strong delivery numbers. Institutions building positions.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#ASTS: 30
#TSM: 26
#GS: 21
#SLV: 20
#IBRX: 18
#SPHL: 14
#TSMC: 13
#EOSE: 12
#GNPX: 11
#IWM: 9
#MS: 9
#AMD: 8
#ROLR: 8
#NVDA: 7
#SPY: 7
#POET: 6
#RB: 6
#BTC: 6

0 0 0 0

@smcapstrategist.bsky.social

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#EOSE: 20
#ROLR: 19
#GNPX: 16
#BTC: 13
#SLV: 13
#NFLX: 12
#GOOGL: 11
#SPY: 11
#NVDA: 10
#BAC: 9
#RIME: 9
#NXXT: 9
#IBRX: 8
#AAPL: 8
#POET: 8
#ADUR: 7
#BABA: 7
#WFC: 7

0 0 0 0

Small Cap Strategist

2 months ago

Trade Alerts, Wednesday January 14, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Wed Jan 14th - #XOMA #WBTN #TBPH #SABS #ACHV #BOOM #CHCO #FOSL #GNPX #IMCC #KXIN #MAZE #NEWT #ORMP #UA #RYAM #PKST #NGVC #LXFR #GCO #FCRS #DCO #CC #ADNT - More: crystalequityresearch.com/trade-alerts... - #smallcap

1 0 0 0

2 months ago

#GNPX seeing significant accumulation and strong volume, signaling strong conviction in the company's potential upside.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#SPY: 25
#JP: 19
#EVTV: 18
#META: 18
#EOSE: 15
#TSLA: 15
#JPM: 14
#ATON: 14
#IREN: 11
#NVDA: 10
#ASST: 10
#GNPX: 10
#GOOGL: 9
#BABA: 9
#INUV: 9
#LITM: 8
#MIGI: 8
#GLD: 7

0 0 0 0

2 months ago

#GNPX shares gain traction after Rep. Tim Moore's significant purchases, fueled by promise of diabetes gene therapy GPX-002.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#SPY: 18
#BABA: 18
#GNPX: 13
#EVTV: 13
#META: 12
#LITM: 11
#GOOGL: 10
#RIME: 10
#ATON: 10
#IREN: 10
#INUV: 9
#JP: 9
#NVDA: 9
#TSLA: 9
#JPM: 8
#AMZN: 8
#ORCL: 8
#SRPT: 8

0 0 0 0

2 months ago

#GNPX gets a boost as Congressman and top 2025 stock picker Tim Moore buys in, citing strong delivery numbers and FDA meeting plans for Q1 2026.

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#SNDK: 12
#GNPX: 10
#TSLA: 9
#OPEN: 9
#WMT: 8
#SPY: 8
#INTC: 8
#MU: 7
#ASTI: 6
#QQQ: 6
#ASTS: 5
#BTC: 5
#IWM: 5
#EOSE: 5
#NVDA: 5
#SP500: 5
#SRPT: 4
#BE: 4

0 0 0 0

2 months ago

Today’s most trending tickers with positive sentiment (last 24h):

#OPEN: 23
#TSLA: 19
#AAPL: 18
#SPY: 18
#GNPX: 13
#SNDK: 12
#INTC: 11
#ASTI: 9
#OKLO: 8
#RKT: 8
#CETX: 8
#NVO: 8
#EOSE: 7
#GME: 7
#NVDA: 7
#IWM: 7
#NXXT: 6
#PRFX: 6

0 0 0 0

Genprex Provides Clinical Update on Diabetes Gene Therapy Program Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.

2 months ago

#GNPX Genprex Provides Clinical Update on Diabetes Gene Therapy Program

www.stocktitan.net/news/GNPX/genprex-provid...

0 0 0 0

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.

2 months ago

#GNPX Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

www.stocktitan.net/news/GNPX/genprex-announ...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Thu Dec 4th - #PMI #WRAP #WNW #SNCR #QCLS #PLBY #MNY #KALA #ILLR #GNPX #DXLG #BIOA #AXGN - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NASDAQ: #GNPX ) Genprex Inc. (NASDAQ: GNPX) Sees Notable Increase in Thursday Morning Market Activity

0 0 0 0

4 months ago

#GNPX Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

www.stocktitan.net/news/GNPX/data-from-genp...

0 0 0 0

4 months ago

#GNPX Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

www.stocktitan.net/news/GNPX/genprex-adds-c...

0 0 0 0

@smcapstrategist.bsky.social

4 months ago

#GNPX Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

www.stocktitan.net/news/GNPX/genprex-announ...

0 0 0 0

Small Cap Strategist

4 months ago

Leading Indicators, Wednesday November 12, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Wed Nov 12th - #SAVA #ORGN #MAMA #LASR #KOPN #ICHR #HCAT #GNPX #ENLV #DOGZ #CBAT #WW #WEST #UROY #TREE #PDFS #BRCB #SHO #RMT #PACS #NRGV #IIPR #HPP #FF #EE - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex (NASDAQ: GNPX) announced that the European Patent Office has communicated its intent to grant a patent for the use of Reqorsa gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer (Nov 4, 2025).This expands Genprex's patent estate that already includes granted patents for the same combination in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Reqorsa is being developed alongside approved cancer drugs for lung cancer, with preclinical data showing complementarity with targeted drugs and immunotherapies.The release cites EU and global lung cancer burden: ~250,000 EU deaths in 2021, 11.9% of new cancer diagnoses in EU-27 (2020), and GLOBOCAN 2022 estimates of ~2.48M new global cases and ~1.8M deaths.

5 months ago

#GNPX Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

www.stocktitan.net/news/GNPX/genprex-announ...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Genprex Initiates $10 Million Direct Offering to Fund Cancer and Diabetes Therapies Genprex, Inc. announces a registered direct offering of up to $10 million to support its gene therapy advancements for cancer and diabetes treatment.

Genprex Initiates $10 Million Direct Offering to Fund Cancer and Diabetes Therapies #gene_therapy #Genprex #GNPX

0 0 0 0